| | | In a survey of nearly 600 respondents, Catalent explored the driving forces & challenges across the orphan drug development and commercialization phases. To learn more about motivations that inspire researchers, how partnerships can play a role in orphan drug development and more, read the survey! 
|
RIGImmune has struck a deal to acquire Subintro, giving it access to novel topical delivery systems. The deal positions the biotech to advance the development of novel RNA therapies and vaccine adjuvants for local mucosal delivery. Bryn Pharma, meanwhile, is using nasal spray technology to try to challenge EpiPen autoinjectors for the autoinjector market. Having wrapped up a pivotal study, the North Carolina-based drug developer is moving forward through the regulatory process. Cingulate's big idea is to enable the timed-release of oral therapies. And, with the idea holding up in an early clinical test, it now has an anxiety prospect to add to its investigational treatments of attention deficit hyperactivity disorder. | Tuesday, October 4, 2022 | 1pm ET / 10am PT This panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture. Register now. |
| By Nick Paul Taylor RIGImmune has struck a deal to acquire Subintro, giving it access to novel topical delivery systems. The deal positions the biotech to advance the development of novel RNA therapies and vaccine adjuvants for local mucosal delivery. |
|
|
By Nick Paul Taylor Bryn Pharma is advancing its nasal spray challenger to EpiPen autoinjectors. Having wrapped up a pivotal study that pitted the two rivals against each other, the North Carolina-based drug developer is moving forward through the regulatory process. By Nick Paul Taylor Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned once-daily therapy. By Kevin Dunleavy On Friday, the FDA approved Aponvie, which becomes the first intravenous P/neurokinin-1 (NK) receptor antagonist available for postoperative nausea and vomiting (PONV) in adults. Delivered in a single 30-second IV injection, Aponvie is the same drug as Merck’s Emend, which is now widely available as a generic. The difference is its IV formulation as opposed to Emend, which is taken in pill form. | With significant market opportunity available and dedicated regulatory pathways defined, the number of orphan drug programs are growing globally. Read this article that shares insights from industry experts on key strategies for managing an orphan drug program. Read now! 
|
| Monday, September 26, 2022 | 11am ET / 8am PT In this webinar Cambrex wil discuss how their facility and the Cambrex network are evolving to enhance capabilities and accelerate API development. Register now. 
|
Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: NetApp Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific | | |
|
